NALTREKSON CİLT ALTI İMPLANT UYGULAMASI SONRASI GELİŞEN CİLT REAKSİYONU

Şafak Yalçın Şahiner; Salih Cihat Paltun; Erol Göka; Hasan Kaya

doi:10.5455/car.105-1513525367

Case Report

NALTREKSON CİLT ALTI İMPLANT UYGULAMASI SONRASI GELİŞEN CİLT REAKSİYONU

Year 2017, , 72 - 74, 07.09.2017

Şafak Yalçın Şahiner Salih Cihat Paltun Erol Göka Hasan Kaya

https://doi.org/10.5455/car.105-1513525367

Abstract

Alkol ve opioid bağımlılıkları tedavisinde ülkemizde yeni alternatifler arasında naltrekson cilt altı implant yer almaktadır. Bulantı, kusma, baş ağrısı, deri döküntüleri, depresyon, kaygı ve enerji kaybı naltrekson kullanımında bildirilen yan etkilerdir. Bu yazıda naltrekson cilt altı implant uygulaması sonrasında kaşıntı ve deri döküntüleri gelişen bir vaka tartışılacaktır.

Keywords

Naltrekson, bağımlılık, kaşıntı

References

1. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49:876-80.
2. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long acting injectable naltrexone for alcohol dependence: a randomized controlled trial. ]AMA 2005;293: 1617-25.
3. Johnson BA, Ait-Daoud N, Aubin H-J, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res 2004; 28:1356-61.
4. Krupitsky EM, Blokhina EA.Long-acting depot formulations of naltrexone for heroin depedence: a review. Curr Opin Psychiatry. 2010; 23:210-4.
5. Şukru Balevi. İlac reaksiyonları. Genel Tıp Dergisi 1997; 7:209-15.
6. Boyvat, Ayşe. İlaç erüpsiyonlarında patogenez ve klinik özellikler. Turkiye Klinikleri Journal of Dermatology Special Topics, 2008, 1.1: 47-57.
7. Erkek E: Kutanoz İlac Reaksiyonları. in: Tuzun Y, Gurer MA, Serdaroğlu S,Oğuz O, Aksungur VL (editorler). Dermatoloji. 3. Baskı, İstanbul: Nobel Tıp Kitabevleri, 2008: 269-316.
8. Martin T, Hui L. Severe cutaneous adverse drug reactions: a review onepidemiology, etiology, clinical manifestation and pathogenesis. Chin Med J. 2008; 121: 756-61.5.
9. Sharma VK, Sethuraman G. Adverse cutaneous reactions to drugs: anoverview. J Postgrad Med 1996; 42: 15-22.
10. Abboud TK, Afrasiabi A. Davidson JMD et al. Prophylactic oral naltrexone with epidural morphine: Effect on adverse reactions and ventilatorj' responses to carbon dioxide. Anesthesiology 1990; 72: 233-7.
11. Peer G, Kivity S, Agami O et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996; 348: 1552-4.
12. Carson KL, Tran 'iT. Cotton P, Sharara Al, Hum CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Anı J Gastroenterol. 1996; 91: 1022-5.
13. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ. 1988; 297: 1501-4.
14. Bergasa NV, Vergalla J, Jones EA. Acute cholestasis in the rat induces mild analgesia; reversal by naloxone. Hepatology. 1990; 12:887.
15. Sullivan JR, Watson A. Naltrexone: a case report of pruritus from an antipruritic. Australas J Dermatol. 1997; 38:196-8.

Year 2017, , 72 - 74, 07.09.2017

Şafak Yalçın Şahiner Salih Cihat Paltun Erol Göka Hasan Kaya

https://doi.org/10.5455/car.105-1513525367

Abstract

References

1. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49:876-80.
2. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long acting injectable naltrexone for alcohol dependence: a randomized controlled trial. ]AMA 2005;293: 1617-25.
3. Johnson BA, Ait-Daoud N, Aubin H-J, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res 2004; 28:1356-61.
4. Krupitsky EM, Blokhina EA.Long-acting depot formulations of naltrexone for heroin depedence: a review. Curr Opin Psychiatry. 2010; 23:210-4.
5. Şukru Balevi. İlac reaksiyonları. Genel Tıp Dergisi 1997; 7:209-15.
6. Boyvat, Ayşe. İlaç erüpsiyonlarında patogenez ve klinik özellikler. Turkiye Klinikleri Journal of Dermatology Special Topics, 2008, 1.1: 47-57.
7. Erkek E: Kutanoz İlac Reaksiyonları. in: Tuzun Y, Gurer MA, Serdaroğlu S,Oğuz O, Aksungur VL (editorler). Dermatoloji. 3. Baskı, İstanbul: Nobel Tıp Kitabevleri, 2008: 269-316.
8. Martin T, Hui L. Severe cutaneous adverse drug reactions: a review onepidemiology, etiology, clinical manifestation and pathogenesis. Chin Med J. 2008; 121: 756-61.5.
9. Sharma VK, Sethuraman G. Adverse cutaneous reactions to drugs: anoverview. J Postgrad Med 1996; 42: 15-22.
10. Abboud TK, Afrasiabi A. Davidson JMD et al. Prophylactic oral naltrexone with epidural morphine: Effect on adverse reactions and ventilatorj' responses to carbon dioxide. Anesthesiology 1990; 72: 233-7.
11. Peer G, Kivity S, Agami O et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996; 348: 1552-4.
12. Carson KL, Tran 'iT. Cotton P, Sharara Al, Hum CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Anı J Gastroenterol. 1996; 91: 1022-5.
13. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ. 1988; 297: 1501-4.
14. Bergasa NV, Vergalla J, Jones EA. Acute cholestasis in the rat induces mild analgesia; reversal by naloxone. Hepatology. 1990; 12:887.
15. Sullivan JR, Watson A. Naltrexone: a case report of pruritus from an antipruritic. Australas J Dermatol. 1997; 38:196-8.

There are 15 citations in total.

Details

Primary Language	Turkish
Subjects	Psychology, Subtance Abuse
Journal Section	Case Reports
Authors	Şafak Yalçın Şahiner This is me Salih Cihat Paltun This is me Erol Göka This is me Hasan Kaya This is me
Publication Date	September 7, 2017
Published in Issue	Year 2017

Cite

APA	Yalçın Şahiner, Ş., Paltun, S. C., Göka, E., Kaya, H. (2017). NALTREKSON CİLT ALTI İMPLANT UYGULAMASI SONRASI GELİŞEN CİLT REAKSİYONU. Current Addiction Research, 1(2), 72-74. https://doi.org/10.5455/car.105-1513525367
AMA	Yalçın Şahiner Ş, Paltun SC, Göka E, Kaya H. NALTREKSON CİLT ALTI İMPLANT UYGULAMASI SONRASI GELİŞEN CİLT REAKSİYONU. Current Addiction Research. September 2017;1(2):72-74. doi:10.5455/car.105-1513525367
Chicago	Yalçın Şahiner, Şafak, Salih Cihat Paltun, Erol Göka, and Hasan Kaya. “NALTREKSON CİLT ALTI İMPLANT UYGULAMASI SONRASI GELİŞEN CİLT REAKSİYONU”. Current Addiction Research 1, no. 2 (September 2017): 72-74. https://doi.org/10.5455/car.105-1513525367.
EndNote	Yalçın Şahiner Ş, Paltun SC, Göka E, Kaya H (September 1, 2017) NALTREKSON CİLT ALTI İMPLANT UYGULAMASI SONRASI GELİŞEN CİLT REAKSİYONU. Current Addiction Research 1 2 72–74.
IEEE	Ş. Yalçın Şahiner, S. C. Paltun, E. Göka, and H. Kaya, “NALTREKSON CİLT ALTI İMPLANT UYGULAMASI SONRASI GELİŞEN CİLT REAKSİYONU”, Current Addiction Research, vol. 1, no. 2, pp. 72–74, 2017, doi: 10.5455/car.105-1513525367.
ISNAD	Yalçın Şahiner, Şafak et al. “NALTREKSON CİLT ALTI İMPLANT UYGULAMASI SONRASI GELİŞEN CİLT REAKSİYONU”. Current Addiction Research 1/2 (September 2017), 72-74. https://doi.org/10.5455/car.105-1513525367.
JAMA	Yalçın Şahiner Ş, Paltun SC, Göka E, Kaya H. NALTREKSON CİLT ALTI İMPLANT UYGULAMASI SONRASI GELİŞEN CİLT REAKSİYONU. Current Addiction Research. 2017;1:72–74.
MLA	Yalçın Şahiner, Şafak et al. “NALTREKSON CİLT ALTI İMPLANT UYGULAMASI SONRASI GELİŞEN CİLT REAKSİYONU”. Current Addiction Research, vol. 1, no. 2, 2017, pp. 72-74, doi:10.5455/car.105-1513525367.
Vancouver	Yalçın Şahiner Ş, Paltun SC, Göka E, Kaya H. NALTREKSON CİLT ALTI İMPLANT UYGULAMASI SONRASI GELİŞEN CİLT REAKSİYONU. Current Addiction Research. 2017;1(2):72-4.